[1] |
RuddKE, JohnsonSC, AgesaKM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study[J]. Lancet, 2020,395(10219):200-211. DOI: 10.1016/S0140-6736(19)32989-7.
|
[2] |
LiuJ, ZhangX, ChengY, et al. Dendritic cell migration in inflammation and immunity[J]. Cell Mol Immunol, 2021,18(11):2461-2471. DOI: 10.1038/s41423-021-00726-4.
|
[3] |
曾茁, 彭毅志, 袁志强. 脓毒症生物标志物的研究进展[J]. 中华烧伤与创面修复杂志, 2023, 39(7): 679-684. DOI: 10.3760/cma.j.cn501225-20230320-00086.
|
[4] |
VolkHD, ReinkeP, KrauschD, et al. Monocyte deactivation--rationale for a new therapeutic strategy in sepsis[J]. Intensive Care Med, 1996,22 Suppl 4:S474-481. DOI: 10.1007/BF01743727.
|
[5] |
WuDD, LiT, JiXY. Dendritic cells in sepsis: pathological alterations and therapeutic implications[J]. J Immunol Res, 2017, 2017:3591248. DOI: 10.1155/2017/3591248.
|
[6] |
PèneF, CourtineE, OuaazF, et al. Toll-like receptors 2 and 4 contribute to sepsis-induced depletion of spleen dendritic cells[J]. Infect Immun, 2009,77(12):5651-5658. DOI: 10.1128/IAI.00238-09.
|
[7] |
GautierEL, HubyT, Saint-CharlesF, et al. Enhanced dendritic cell survival attenuates lipopolysaccharide-induced immunosuppression and increases resistance to lethal endotoxic shock[J]. J Immunol, 2008,180(10):6941-6946. DOI: 10.4049/jimmunol.180.10.6941.
|
[8] |
CremerI, Dieu-NosjeanMC, MaréchalS, et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction[J]. Blood, 2002,100(10):3646-3655. DOI: 10.1182/blood-2002-01-0312.
|
[9] |
WongBR, JosienR, LeeSY, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor[J]. J Exp Med, 1997,186(12):2075-2080. DOI: 10.1084/jem.186.12.2075.
|
[10] |
Ricaño-PonceI, RizaAL, de NooijerAH, et al. Characterization of sepsis inflammatory endotypes using circulatory proteins in patients with severe infection: a prospective cohort study[J]. BMC Infect Dis, 2022,22(1):778. DOI: 10.1186/s12879-022-07761-0.
|
[11] |
WangLX, RenC, YaoRQ, et al. Sestrin2 protects against lethal sepsis by suppressing the pyroptosis of dendritic cells[J]. Cell Mol Life Sci, 2021,78(24):8209-8227. DOI: 10.1007/s00018-021-03970-z.
|
[12] |
LiJY, RenC, WangLX, et al. Sestrin2 protects dendrite cells against ferroptosis induced by sepsis[J]. Cell Death Dis, 2021,12(9):834. DOI: 10.1038/s41419-021-04122-8.
|
[13] |
FrenckRW, SarmanG, HarperTE, et al. The ability of recombinant murine granulocyte-macrophage colony-stimulating factor to protect neonatal rats from septic death due to Staphylococcus aureus[J]. J Infect Dis, 1990,162(1):109-114. DOI: 10.1093/infdis/162.1.109.
|
[14] |
BoL, WangF, ZhuJ, et al. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis[J]. Crit Care, 2011,15(1):R58. DOI: 10.1186/cc10031.
|
[15] |
MeiselC, SchefoldJC, PschowskiR, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial[J]. Am J Respir Crit Care Med, 2009,180(7):640-648. DOI: 10.1164/rccm.200903-0363OC.
|
[16] |
DonnenbergVS, O'ConnellPJ, LogarAJ, et al. Rare-event analysis of circulating human dendritic cell subsets and their presumptive mouse counterparts[J]. Transplantation, 2001,72(12):1946-1951. DOI: 10.1097/00007890-200112270-00014.
|
[17] |
AnandasabapathyN, BretonG, HurleyA, et al. Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers[J]. Bone Marrow Transplant, 2015,50(7):924-930. DOI: 10.1038/bmt.2015.74.
|
[18] |
PatilNK, BohannonJK, LuanL, et al. Flt3 ligand treatment attenuates T cell dysfunction and improves survival in a murine model of burn wound sepsis[J]. Shock, 2017, 47(1):40-51. DOI: 10.1097/SHK.0000000000000688.
|
[19] |
HundeshagenG, CuiW, MusgroveL, et al. Fms-like tyrosine kinase-3 ligand attenuates local and systemic infection in a model of post-burn pneumonia[J]. Shock, 2018, 49(6):721-727. DOI: 10.1097/SHK.0000000000000964.
|
[20] |
BhardwajN, FriedlanderPA, PavlickAC, et al. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets[J]. Nat Cancer, 2020,1(12):1204-1217. DOI: 10.1038/s43018-020-00143-y.
|
[21] |
OberholzerA, OberholzerC, EfronPA, et al. Functional modification of dendritic cells with recombinant adenovirus encoding interleukin 10 for the treatment of sepsis[J]. Shock, 2005,23(6):507-515.
|
[22] |
ZhuXM, YaoYM, LiangHP, et al. The effect of high mobility group box-1 protein on splenic dendritic cell maturation in rats[J]. J Interferon Cytokine Res, 2009,29(10):677-686. DOI: 10.1089/jir.2008.0104.
|
[23] |
徐姗, 姚咏明, 董宁, 等. 高迁移率族蛋白B1对大鼠脾脏树突状细胞表面共刺激分子表达的影响[J].中华创伤杂志,2006,22(8):579-583. DOI: 10.3760/j:issn:1001-8050.2006.08.005.
|
[24] |
NakosG, Malamou-MitsiVD, LachanaA, et al. Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma[J]. Crit Care Med, 2002,30(7):1488-1494. DOI: 10.1097/00003246-200207000-00015.
|
[25] |
PayenD, FaivreV, MiatelloJ, et al. Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression: a case series[J]. BMC Infect Dis, 2019, 19(1):931. DOI: 10.1186/s12879-019-4526-x.
|
[26] |
LeentjensJ, KoxM, KochRM, et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study[J]. Am J Respir Crit Care Med, 2012,186(9):838-845. DOI: 10.1164/rccm.201204-0645OC.
|
[27] |
ShaoR, FangY, YuH, et al. Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study[J]. Crit Care, 2016,20(1):124. DOI: 10.1186/s13054-016-1301-x.
|
[28] |
ChangK, SvabekC, Vazquez-GuillametC, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis[J]. Crit Care, 2014,18(1):R3. DOI: 10.1186/cc13176.
|
[29] |
HotchkissRS, ColstonE, YendeS, et al. Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab[J]. Intensive Care Med, 2019,45(10):1360-1371. DOI: 10.1007/s00134-019-05704-z.
|
[30] |
HotchkissRS, ColstonE, YendeS, et al. Immune checkpoint inhibition in sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of antiprogrammed cell death-ligand 1 antibody (BMS-936559) [J]. Crit Care Med, 2019, 47(5):632-642. DOI: 10.1097/CCM.0000000000003685.
|
[31] |
WangWD, YangXR, GuoMF, et al. Up-regulation of BTLA expression in myeloid dendritic cells associated with the treatment outcome of neonatal sepsis[J]. Mol Immunol, 2021,134:129-140. DOI: 10.1016/j.molimm.2021.03.007.
|
[32] |
ChengT, BaiJ, ChungCS, et al. Enhanced innate inflammation induced by anti-BTLA antibody in dual insult model of hemorrhagic shock/sepsis[J]. Shock, 2016, 45(1):40-49. DOI: 10.1097/SHK.0000000000000479.
|
[33] |
BenjamimCF, LundySK, LukacsNW, et al. Reversal of long-term sepsis-induced immunosuppression by dendritic cells[J]. Blood, 2005,105(9):3588-3595. DOI: 10.1182/blood-2004-08-3251.
|
[34] |
WangHW, YangW, GaoL, et al. Adoptive transfer of bone marrow-derived dendritic cells decreases inhibitory and regulatory T-cell differentiation and improves survival in murine polymicrobial sepsis[J]. Immunology, 2015,145(1):50-59. DOI: 10.1111/imm.12423.
|
[35] |
GaoS, ZengL, ZhangX, et al. Attenuated Streptococcus pneumoniae vaccine candidate SPY1 promotes dendritic cell activation and drives a Th1/Th17 response[J]. Immunol Lett, 2016, 179:47-55. DOI: 10.1016/j.imlet.2016.08.008.
|